Neumora Therapeutics is a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Neumora is redefining neuroscience research and development with a data-driven precision neuroscience platform to cut through brain disease heterogeneity to match the right patient populations to targeted therapeutics. The Company's precision data science platform integrates multiple data types to define patient subtypes through the development of Data Biopsy Signatures™ and Precision Phenotypes™. Neumora is relentless in its commitment to discovering, developing and commercializing targeted therapies for people living with brain diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/07/21 | $500,000,000 | Series A |
ARCH Venture Partners | undisclosed |
